Earnings Call · Q3 FY2023·2023-11-13

Q3 23EPS 0.00%·Rev n/aQ2 23EPS -7.41%·Rev n/aQ1 23EPS +3.92%·Rev n/aQ4 22EPS -75.00%·Rev n/a⚠ consensus missing

Tvardi Therapeutics, Inc. TVRD

Matt Murphy — Investor Relations or similar (not explicitly stated but inferred from context)

Chris Posner — Chief Executive Officer

Ryan Maynard — Chief Financial Officer

−7.2%1d on move date−9.1% vs SPY3d−7.6%5d−10.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TVRD calls or request research access.

More TVRD calls Browse calls Request research access